BlueOcean to tap “three huge markets” with the benefits of cannabis and sea
BlueOcean NutraSciences Inc. (TSXV: BOC) has developed a science-based approach to leverage its current access to 63 retail stores and large online distributors such as Amazon to capitalize on three prominent nutraceutical market segments: heart health, joint health and sport supplements totaling $13B, and the emerging cannabis industry.
In doing so, BlueOcean management is showing deep understanding of the principles to breaking through the fiercely competitive nutratraceutical market: Innovation to stay ahead of the curve, and tapping into established product distribution.
As far as innovation is concerned management is showing plenty. BlueOcean has entered the market with a line of sustainable omega-3/astaxanthin shrimp oil products, which are muscling innovation in the rapidly growing Omega-3 oil market where krill oil has been king as a source of astaxanthin.
Astaxanthin is sold for the treatment of Alzheimer’s disease, Parkinson’s disease, “brain attack” (stroke), high cholesterol, and an eye condition called age-related macular degeneration (AMD).
Astaxanthin is an antioxidant that resembles the carotene of carrots and is toted as the next wonder antioxidant. Astaxanthin also gives salmon flesh its unique color. It is abundant is krill, which are small crustaceans and are found in all the world’s oceans. Blue whale eat krill.
Wild Pacific salmon, especially sockeye salmon, have a high astaxanthin content. However one has to eat about 6 ounces (165 grams) daily to get a 3.6 milligram dose.
Get our daily investorintel update
Over the last few years krill oil has been marketed as the ultimate source of astaxanthin but laboratory results show Blue Ocean’s shrimp oil contains ten times more astaxanthin that the leading krill oil brand.
This puts BlueOcean to tap three huge markets.
Heart health supplements are a $4B market and are dominated by omega-3 products. Krill and shrimp oil alone are expected to make up a $2.3B market by 2020.
Sport supplements are a $10B global market. Muscle endurance and post-exercise recovery are the key benefits sought by consumers.
Joint and bone health supplements make up a $9B market, which targets inflammation as the primary source of joint pain.
Speaking of joint pain, Blue Ocean announced that it has begun the development of a formulation of hemp extract containing cannabinoids (not including the psychoactive drug THC) in combination with its signature Omega-3 Astaxanthin oil from shrimp.
The product line is to be branded “SeaBD” with an expected launch as a dietary supplement into the United States market. Hemp extracts combined with BlueOcean’s natural omega-3 astaxanthin oils are a natural combination as an antioxidant supplement and one that should appeal to the fast-growing cannabiphyllic market.
Surveys show that a large of consumers makes use of nutraceuticals. The nutraceutical industry has been one of the fastest growing industries for two decades. It is supported by an unprecedented demand for more natural health solutions, a fundamental shift toward food and naturally functional food-based ingredients.
The rising cost of healthcare expenditures by consumers around the world is expected to continue to drive usage of nutraceutical. Moreover, some nutraceuticals are regarded as alternatives to over the counter and prescription drugs
The Company’s products are available for sale on five online sites (Amazon.com, Luckyvitamin.com, VitaminWorld.com and Inboxfitness.com) and in 30 Vitamin World stores in the US to date with more online and in-store retail sales channels being aggressively pursued along with further bulk Omega-3 shrimp oil sales.
Dr. Luc C. Duchesne is a Speaker and Author with a PhD in Biochemistry. With three decades of scientific and business experience, he has published ... <Read more about Dr. Luc Duchesne>